Genomic alteration spectrum of NSCLC patients.
, 2022-05-18 14:23:07,
Introduction
Lung cancer is the leading cause of cancer deaths worldwide and is responsible for 30% of all cancer deaths in China.1 With the development of precision medicine and next-generation sequencing (NGS) technology, cancer patients have increasingly benefited from gene detection based targeted therapy. In addition to identifying actionable alterations for targeted therapy, gene detection can also monitor molecular clonal tumor evolution, indicate disease progression and prognosis, and predict drug efficacy and resistance. Marked research interest has been focused on genetic alteration and targeted drugs, particularly directed to non-small cell lung cancer (NSCLC), such that gene detection has become a frontline clinical test.2,3 However, previous studies have indicated that NSCLC showed genetic disparities based on geography and ethnicity, and most of the studies that characterized the tumor genotyping of NSCLC, have been conducted in clinical drug trials.4 Therefore, there is a critical need for real-world genomic alteration profiles for East-China Chinese NSCLC patients.
Sampling methods for gene detection testing consist of tissue biopsy and liquid biopsy. Although tumor tissue for genotyping is considered the gold standard, it is plagued with certain disadvantages, such as the need for invasive tumor sampling and inter- and intratumoral heterogeneity.5 In contrast, liquid biopsy has evolved into either a supplement or even a preferred substitute for tissue biopsy due to its minimal invasiveness and impressive technical advances.5–7
The aim of the present cross-sectional study was to characterize the genetic testing of 3000 East-China Chinese patients diagnosed with NSCLC.
Materials and Methods
Patients and specimens. The study comprised 3000 NSCLC…
,
To read the original article, go to Click here